Table 2.

Previously described pediatric ECMO patients with HIT requiring alternative anticoagulant.

Reference	Age/Sex	Reason for ECMO	C/I for Heparin	Anticoagulant	Initial Bolus (mcg/kg)	Infusion Dose (mcg/kg/min)	Target aPTT (sec)	Duration of ECMO	Complications
Mejak et al. (49)	2 w/F	Myocardial dysfunction after cardiac surgery	HIT	Argatroban				N/A	N/A
Scott et al. (50)	17 m/M	Respiratory failure	HIT	Argatroban	None	1–2	180–200*	9 d	Renal failure
Deitcher et al. (29)	4 y/F	DCM bridge to transplant	HIT	Lepirudin	400	N/A	1.5–2.5 times the baseline	13 d	Uncontrolled bleeding after transplant, death
Tcheng and Wong (51)	8 y/M	DCM	HIT	Argatroban	.5	.5–1.5	2 times the baseline	6 d	None
	16 y/M	OHT d/t ICM, acute rejection	History of HIT	Argatroban	2	.6–2	2 times the baseline	10 d	None
	15 m/F	DCM, heart failure	HIT	Argatroban	2	2–24	2 times the baseline	39 d	None
Potter et al. (34)	1 y/F	MI post cardiac surgery, bridge to transplant	HIT	Argatroban	7 (ECMO priming)	1	250–300*	>13 d	None
	11 d/F	Myocarditis	HIT	Argatroban	11 (ECMO priming)	.1	N/A	10 d	Disseminated thrombi formation, death 2 minutes after ECMO started
	6 d/F	Myocardial dysfunction after cardiac surgery	HIT	Argatroban	10 (ECMO priming)	.5	200–220*	7 d	Disseminated thrombi formation, death
Knoderer et al. (38)	21 m/M	Myocardial dysfunction after cardiac surgery	HIT	Lepirudin
Dager et al. (37)	17 y/F	Respiratory failure d/t bilateral pulmonary contusions	Suspected HIT	Lepirudin	100	120	2 times the baseline	11 d	Respiratory failure, death
Alsoufi et al. (35)	1 w/F	Myocardial dysfunction after cardiac surgery	HIT	Argatroban	50 (ECMO priming)	.15–1.8	200*	N/A	Pulmonary embolism, death

DCM, dilated cardiomyopathy; ICM, idiopathic cardiomyopathy; OHT, orthotropic heart transplant; MI, myocardial infarction; C/I, contraindication; d/t, due to.

^*ACT (sec) rather than aPTT.